Takeda, Hutchmed hook up on cancer drug for $1.13BValuation example. By the way, HutchMed is the big pharma of Li Ka Shing's family.
Takeda, Hutchmed hook up on cancer drug for $1.13B Takeda has gained commercial rights to Hutchmed's cancer drug fruquintinib
outside of China for
$400M up front, plus
$730M in potential milestones.
The latest big pharma player to get a piece of the action however is closer to home. Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments.